Wave Life Sciences will use Deep Genomics’ machine learning-driven biomedical platform to discover novel therapies for treating genetic neuromuscular disorders, the companies said today, through a collaboration whose value was not disclosed. Under the collaboration, the companies have agreed to analyze and test oligonucleotides against potential therapeutic targets within multiple…

A messenger RNA (mRNA) does more than provide ribosomes a template for creating a sequence of amino acids. It also conveys regulatory information, including so-called stop codons. But just as cars sometimes drive through stop signals on the road, ribosomes sometimes “read through” an mRNA’s stop codon, staying attached to…

A platform for gene delivery and tumor therapy has been introduced that harnesses the power of the CRISPR/Cas9 gene-editing system. At the same time, the platform avoids some of the drawbacks of the CRISPR-Cas9 system. Specifically, the platform can cope with CRISPR-Cas9’s sheer bulk, achieving highly efficient and targeted delivery…

It’s one of the highest-stakes races in all of biopharma. Top scientists around the globe are jockeying to be first with an approved CRISPR-based treatment. The breakthrough gene editing technique, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), arrived on the scene just a few years ago. But already a handful…

Synpromics says growing global demand has prompted the developer of gene control and synthetic promoter technology to relocate to expanded facilities in Edinburgh, Scotland. The company has moved into more than 5,000 square feet at the Roslin Innovation Centre, based at the University of Edinburgh’s Easter Bush Campus. Synpromics’ new…

Natera yesterday reported a 6.8% year-over-year decline in fourth-quarter revenues, though revenues for all of 2016 rose 14% over 2015, and the company’s number of tests processed jumped last year. The developer of molecular diagnostic tests reported Q4 revenues of $49.3 million, down from $52.9 million in the year-ago quarter.…